Login
Contact

Explore

Explore

About
  • People and Partners
  • TRI Building
  • Reconciliation Action Plan
  • Strategic Plan
  • TRI Foundation
  • Careers
Research
  • Collaborate
  • Discovery
  • Translate
  • Engage
  • Research Areas
Clinical
  • Translational Trials
  • Clinical Research Facility
  • TRI at Children’s
Industry
  • TRI Incubator
  • The Precinct
  • Residents
Manufacture
  • New cGMP Facility
Facilities
  • Cleanroom
  • Flow Cytometry
  • Histology
  • Microscopy
  • Proteomics
  • Preclinical Imaging
  • Biological Research
  • Gnotobiotics
  • Human Immune Model
Get Involved
  • Health Consumers
  • SPARQ-ed
Resources
  • News
  • Events
  • Case Studies
  • Grants and Funding
  • Education and Training

+61 7 3443 7000info@tri.edu.au37 Kent Street, Woolloongabba QLD 4102 Australia

Acknowledgement of Country

TRI acknowledges the traditional custodians of the land we are on today, the Turrbal and Jagera people and we recognise their continuing connection to land, waters and community. We pay deep respect to them and their cultures; and to Elders past, present and emerging.

© Translational Research Institute Pty Ltd atf the Translational Research Institute Trust|ABN: 58 155 991 662
Privacy policy|Terms of Use|Contact Us
TRI · Industry

Industry

IndustryTRI IncubatorThe PrecinctResidents

Industry at TRI

The TRI community is made up of a network of researchers, clinicians, consumers and industry. These networks intersect in collaborations across the translational pathway – enabling knowledge sharing, supporting innovation, and fast-tracking medical solutions that create healthier lives.
industry

Industry @ TRI: Microbio

TRI is transforming Australia’s healthcare future through an expanding network of biotech and medtech startups and scale ups.

Microbio, based at TRI, is revolutionising pathogen detection. The Australian biotech scale-up has developed a rapid bloodstream infection test and two COVID-19 tests that have been cleared for sale in Europe.

industry

Industry @ TRI: Microbio

TRI is transforming Australia’s healthcare future through an expanding network of biotech and medtech startups and scale ups.

Microbio, based at TRI, is revolutionising pathogen detection. The Australian biotech scale-up has developed a rapid bloodstream infection test and two COVID-19 tests that have been cleared for sale in Europe.

Translational Manufacturing

Countdown to TM@TRI

Australia’s first purpose-built biomedical translational manufacturing facility, Translational Manufacturing @ TRI (TM@TRI) will support Medtech and Biotech businesses to expand and manufacture at scale in Queensland.

This will be the only facility in the country where start-up biomedical companies can access cGMP ready cleanrooms, autoclave, and production facilities. Proudly funded in partnership with the Queensland Government, TM@TRI will put Queensland on the map globally, and fill the infrastructure gap for incubator companies, accelerating healthcare intervention development and commercialisation.

Translational Manufacturing

Countdown to TM@TRI

Australia’s first purpose-built biomedical translational manufacturing facility, Translational Manufacturing @ TRI (TM@TRI) will support Medtech and Biotech businesses to expand and manufacture at scale in Queensland.

This will be the only facility in the country where start-up biomedical companies can access cGMP ready cleanrooms, autoclave, and production facilities. Proudly funded in partnership with the Queensland Government, TM@TRI will put Queensland on the map globally, and fill the infrastructure gap for incubator companies, accelerating healthcare intervention development and commercialisation.

The Vaxxas Journey

In 2014, TRI became home to Australian biotech, Vaxxas, a company which is set to revolutionise vaccine delivery through their innovative High-Density Microarray Patch technology.

The patch is made up of thousands of micro-projections that are a quarter of a millimetre long and dry-coated in vaccine. When applied to the skin for a few seconds, the technology directly deposits vaccine within the dense population of key immune cells in the skin.

In 2022 Vaxxas published findings from a pre-clinical trial which showed that their patch was approximately 11 times more effective at combatting the Omicron COVID-19 variant when compared with the same vaccine administered via a needle.

Vaxxas has raised $34 million through an investment round led by OneVentures and UniQuest to progress multiple vaccine programs and received $8.2 million from the Australian government ’s Modern Manufacturing Initiative.

In 2023 Vaxxas moved offsite to their own premises and demonstrate an exciting success story from within our Industry network.

“TRI has given us credibility with our industry partners, governments, and pharma companies that come to visit us from overseas, when they walk into the TRI, all of a sudden our status is lifted, and it goes a long way to getting the contracts that we did working in this environment.”  

Mike Junger

Senior Vice President Advanced Technology, Vaxxas

Industry Engagement: 
Glenda Colburn

“I connect with people and create connections between people”

My role is to help grow networks and ensure the companies housed here can access the supports they need to mature their products for market – from introductions to venture capital firms, quality and regulatory checks, tax advisors, IP attorneys, or clinical trial providers.

A key focus for me is enabling collaborations and initiatives that promote innovation, acceleration, and integration.

I am proud to be a part of these journeys and to be able to offer the world-class facilities, resources, and support services we do at TRI.

Discover the supports and connections available at TRI